白细胞介素—2第17和20位残基在结构功能中的重要性研究

用基因定位突变法,将白细胞介素－２分子中１７Ｌｅｕ和２０Ａｓｐ进行一系列突变,并测定各突变体生物活性与空间结构的变化。分析结果表明１７Ｌｅｕ突变为Ａｓｐ时,ＩＬ－２的空间结构无明显变化,生物活性却显著下降;２０Ａｓｐ突变的为Ｌｅｕ,以及１７Ｌｅｕ与２０Ａｓｐ对调后,均导致ＩＬ－２的空间结构发生变化,并严重影响其生物活性,上述结果说明１７Ｌｅｕ突变为Ａｓｐ后对活性的影响并非由空间结构变化所引起,而与     

人白细胞介素－2第20位残基局部空间结构稳定位对活性的影响

用寡核苷酸诱导的基因定位突变法,将人白细胞介素－２（ＩＬ－２）第２０位Ａｓｐ分别突变为Ａｒｇ、Ｌｙｓ．和Ａｓｎ,比较第２０位残基碱性基因对ＩＬ－２活力的影响,结果２０Ａｓｐ突变为碱性残基时,ＩＬ－２活性急剧下降,但突变为Ａｒｇ时所导致的活性下降较突变为Ｌｙｓ严重３０００倍以上,从空间结构变化上对这２个碱性残基造成的如此大的活性差异进行了分析,发现２０Ａｒｇ突变后对。１２１Ｔｒｐ的微环境有极为显著的影响。结果提示２０Ａｓｐ在与β亚基作用的同时,其局部空间结构的稳定对维持ＩＬ－２的生物学活性也有重要作用。     

人白细胞介素—2第20位残基局部空间结构稳定性对活性的影响

用寡核苷酸诱导的基因定位突变法,将人白细胞介素－２（ＩＬ－２）第２０位Ａｓｐ分别突变为Ａｒｇ,Ｌｙｓ和Ａｓｎ,比较第２０位残基碱性基团对ＩＬ－２活力的影响,结果＾２０Ａｓｐ突变为碱性残基时,ＩＬ－２活性急剧下降,但突变为Ａｒｇ时所导致的活性下降较突变为Ｌｙｓ时所导致的活性下降较突变为Ｌｙｓ严重３０００倍以上。从空间结构变化上对这２个碱性残基造成的如此大的活性差异进行了分析,发现＾２０Ａｒｇ突变后对     

IL—2部分拮抗剂可用于IL—2突变体对受体亚基结合能…

用定点突变法分别得到了两个人白细胞介素－２（ＩＬ－２）的部分拮抗剂１５Ｖａｌ－ＩＬ－２和１２６Ａｓｐ－ＩＬ－２以及一个为ＩＬ－２受体ａ亚基结合缺陷型的突变体６２Ｌｅｕ－ＩＬ－２,当将１５Ｖａｌ－ＩＬ－２或１２６Ａｓｐ－ＩＬ－２与６２Ｌｅｕ－Ｉｌ－２共同保温时,６２Ｌｅｕ－ＩＬ－２的活性受到明显抑制,对此现象机理的分析表明１５Ｖａｌ－ＩＬ－２或１２６Ａｓｐ－ＩＬ－２可用于ＩＬ－２受体亚基结合缺陷型突     

白细胞介素－2镇痛功能位点的研究

白细胞介－２（ＩＬ－２）是重要的免疫调节因子,近来发现还有中枢镇痛作用,用不同ＩＬ－２突变体测定其对大鼠痛阈的影响,发现完全丧失免疫刺激作用的２０Ｌｅｕ－ＩＬ－２（２０Ａｓｐ→Ｌｅｕ）仍能显著提高大鼠的痛阈,其作用强度与天然ＩＬ－２无显著差异,而另一突变体４５Ｖａｌ－ＩＬ－２（４５Ｔｙｒ→Ｖａｌ）虽保留免疫学活性却不能提高大鼠的痛阈;这些结果证明ＩＬ－２分子中具有镇痛作用与具有免疫作用与具有免疫作     

白细胞介素—2分子α螺旋B中的活性相关区域

根据人白细胞介素－２（ＩＬ－２）α螺旋Ｂ中氨基酸残基的空间分布选择性地突变了一些氨基酸残基,结果发现：５７Ｇｌｎ→Ｇｌｕ,６２Ｇｌｕ→Ｌｅｕ,６２Ｇｌｕ→Ａｒｇ和６５Ｐｒｏ→Ａｒｇ这些替换均使ＩＬ－２活性显著降低或丧失,而６３Ｌｅｕ→Ｓｅｒ或６４Ｌｙｓ→Ａｌａ对ＩＬ－２活性影响不大。从受体竞争抑制结合实验结果可知,上述不表现活性的突变体也同时丧夫了与高亲和力受体的结合能力,这说明α螺旋Ｂ中这些位点     

白细胞介素－2分子α螺旋B中的活性相关区域

根据人白细胞介素－２（ＩＬ－２）ａ螺旋Ｂ中氨基酸残基的空间分布选择性地突变了一些氨基酸残基,结果发现．５７Ｇｌｎ→Ｇｌｎ,６２Ｇｌｎ→Ｌｅｕ,６２Ｇｌｎ→Ａｒｇ和６５Ｐｒｏ→Ａｒｇ这些替换均使ＩＬ－２活性显著降低或丧失,而６３Ｌｅｕ→Ｓｅｒ或６４Ｌｙｓ→Ａｌａ对ＩＬ－２活性影响不大。从受体竞争抑制结合实验结果可知,上述不表现活性的突变体也同时丧失了与高亲和力受体的结合能力,这说明α螺旋Ｂ中这些位点对ＩＬ－２与受体结合有贡献,事实上,那些直接与受体β、γ亚基结合的残基所在螺旋为Ａ、Ｄ螺旋而非α螺旋Ｂ,由此我们认为α螺旋Ｂ虽不直接参与与受体β、γ亚基结合,但它在空间结构上对ＩＬ－２与受体β、γ亚基的结合产生了有利的影响,而５７Ｇｌｎ、６２Ｇｌｎ、６５Ｐｒｏ等残基则在此过程中发挥重要作用。     

人白细胞介素－2的两个部分拮抗剂

通过定点诱变技术得到６个生物活性剧烈下降的人白细胞介素－２（ＩＬ－２）突变体,其中两个突变体即１５Ｖａｌ－ＩＬ－２和１２６Ａｓｐ－ＩＬ－２可以在一定浓度范围内使ＩＬ－２的生物效应降低。在对高亲和力ＩＬ－２受体（ＩＬ－２Ｒ）的竞争抑制实验中,１５Ｖａｌ－ＩＬ－２和１２６Ａｓｐ－Ｉｌ－２又表现了一定的竞争能力。这些结果表明１５Ｖａｌ－ＩＬ－２和１２６Ａｓｐ－ＩＬ－２可部分拮抗天然ＩＬ－２的作用。结合Ｉ     

白细胞介素－2中某些残基替换对活性的影响

用基因定点突变法研究了白细胞介素－２（ＩＬ－２）中某些氨基酸对生物活性的影响。将ＩＬ－２中３９Ｍｅｔ和４３Ｌｙｓ分别改为Ｐｒｏ,企图破坏此处α螺旋,突变体的ＣＤ图谱和生物活性均,不变,说明此处可能原来就不存在α螺旋．而将５２Ｇｌｕ．５３Ｌｅｕ,５４Ｌｙｓ分别改为Ｐｒｏ后,ＣＤ谱发生了变化,生物活性也显著下降。表明这些氨基酸处在α螺旋中,将它们改为Ｐｒｏ后,影响了ＩＬ－２的结构,并导致活性下降     

蛇毒锯鳞蝰素基因Leu14—Lys15—Glu16的定点突变

本研究的目是的利用蛋白质工程定点突变的方法,在蛇毒锯鳞蝰素基因分子上增加另一个保守序列ＲＧＤ（１４位精氨酸残基,１５位甘氨酸残基,１６位天氨酸残基）,以其增加该分子的生物活性,并探讨蛋白质一级结构,空间结构和功能的关系,在质粒ｐＪＣ６４的基础上,利用ＰＣＲ定点突变方法,对蛇毒锯鳞蝰素基因Ｌｅｕ１４－Ｌｙｓ１５－Ｇｌｕ１６进行定点突变,使相应的ＰＣＲ定点突变方法,对蛇毒锯鳞蝰素基因Ｌｅｕ１４－Ｌｙｓ     

大肠杆菌tRNA~(Leu)的提取、纯化及性质研究

采用高表达大肠杆菌ｔＲＮＡＬｅｕ菌株提取、纯化了亮氨酸等受体转移核糖核酸ｔＲＮＡＬｅｕ１和ｔＲＮＡＬｅｕ２．利用稳态动力学手段研究了ｔＲＮＡＬｅｕ１及脱镁ｔＲＮＡＬｅｕ１在不同稀土离子作用下与纯化亮氨酰－ｔＲＮＡ合成酶的氨酰化作用．ｔＲＮＡＬｅｕ１与亮氨酰－ｔＲＮＡ合成酶的结合及催化效率均受参与稀土离子的影响,表观Ｋｍ值有较明显的变化．结果表明,亮氨酰－ｔＲＮＡ合成酶催化的ｔＲＮＡＬｅｕ１氨酰化反应所需Ｍｇ２＋能够被稀土离子取代,但亲合性能不同．     

Export of unprocessed precursor maltose-binding protein to the periplasm of Escherichia coli cells.

The Escherichia coli maltose-binding protein (MBP) R2 signal peptide is a truncated version of the wild-type structure that still facilitates very efficient export of MBP to the periplasm. Among single amino acid substitutions in the R2 signal peptide resulting in an export-defective precursor MBP (pMBP) were two that replaced residues in the consensus Ala-X-Ala sequence (residues -3 to -1) that immediately precedes the cleavage site. It was suggested that the functional hydrophobic core and signal peptidase recognition sequence of this signal peptide substantially overlap and that these two alterations affect both pMBP translocation and processing. In this study, the export of pMBP by the mutants, designated CC15 and CC17, with these two alterations was investigated further. The pMBP of mutant CC17 has an Arg substituted for Leu at the -2 position. It was found that CC17 cells exported only a very small amount of MBP, but that which was exported appeared to be correctly processed. This result was consistent with other studies that have concluded that virtually any amino acid can occupy the -2 position. For mutant CC15, which exhibits a fully Mal+ phenotype, an Asp is substituted for the Ala at the -3 position. CC15 cells were found to export large quantities of unprocessed, soluble pMBP to the periplasm, although such export was achieved in a relatively slow, posttranslational manner. This result was also consistent with other studies that suggested that charged residues are normally excluded from the -3 position of the cleavage site. Using in vitro oligonucleotide-directed mutagenesis, we constructed a new signal sequence mutant in which Asp was substituted for Arg at the -3 position of an otherwise wild-type MBP signal peptide. This alteration had no apparent effect on pMBP translocation across the cytoplasmic membrane, but processing by signal peptidase was inhibited. This pMBP species with its full-length hydrophobic core remained anchored to the membrane, where it could still participate in maltose uptake. The implications of these results for models of protein export are discussed.     

Rational design, conformational studies and bioactivity of highly potent conformationally constrained calcitonin analogues.

Calcitonin is known for its hypocalcaemic effect and the inhibition of bone resorption, and is used therapeutically for the treatment of osteoporosis and Paget's disease. Our studies on the conformational features of human calcitonin (hCt) bioactivity have led to the conformationally constrained hCt analogue cyclo17,21-[Asp17, Lys21]hCt (1), which had a 5-10 times higher in vivo hypocalcaemic potency than hCt [Kapurniotu, A. & Taylor, J.W. (1995) J. Med. Chem. 38, 836-847]. We hypothesized that a stabilized, possibly type I beta turn/beta sheet conformation between residues 17 and 21 could play a crucial role in hCt bioactivity. Here, we designed, synthesized and studied the conformation and bioactivity of 19-member to 17-member ring-size analogues of 1 with the structure cyclo17,21-[Asp17,XX21]hCt with XX = Orn (2), Dab (3) and Dap (4), of the control peptide [Asp17,Orn21]hCt (5), and of the 19-member cyclo17,21-[Glu17,Dab21]hCt (6). Analyses of the far-UV CD spectra indicated increased type I beta turn and antiparallel beta sheet content in the bicyclic analogues compared with hCt. In the in vivo hypocalcaemic assay, cyclo17,21-[Asp17,Orn21]hCt (2) was found to have a 400-fold higher potency than hCt and was fourfold more potent than salmon calcitonin (sCt), which has been the most potent known Ct. Analogue 3 had a 30-fold higher potency than hCt, whereas the highly constrained analogue 4 was as potent as hCt. Bioactivity was not enhanced for the nonbridged compound [Asp17, Orn21]hCt (5), whereas cyclo17,21-[Glu17,Dab21]hCt (6) showed the same bioactivity as 1. This study identifies 2 as exhibiting the highest in vivo potency among currently known Cts, while it differs in only one amino acid residue from hCt, strongly suggesting that the introduced constraint may have served in 'freezing' hCt in a bioactive conformation. Our findings provide evidence for the first time that a beta turn/beta sheet conformation in region 17-21 of hCt and the topological features of the side chain of Asn17 are strongly associated with in vivo bioactivity, and offer a novel lead structure for a hCt-based drug for the treatment of osteoporosis and other bone-disorder-related diseases.     

Mutational analysis of chicken interleukin 2

Chicken interleukin 2 (chIL-2) has low, but significant, homology to both mammalian IL-2 and mammalian IL-15. In view of its unique phylogenetic position and potential use as a vaccine adjuvant, a detailed mutational analysis for critical functional sites was undertaken. It was found that Asp17 is a critical N terminal contact site for binding to the putative chIL-2 receptor, which is similar to results obtained for mammalian IL-2 and IL-15. Analysis of the C terminus did not reveal a single critical amino acid. However, deletion mutant studies demonstrated that removal of C terminal amino acids yielded proteins with decreased bioactivity and that this decrease was a function of the number and kind of amino acids removed. This study is the first non-mammalian IL-2 mutational analysis and proposes a model for the interaction between chIL-2 and its receptor.     

Preparation, purification, and determination of the biological activities of 12 N terminus-truncated recombinant analogues of bovine placental lactogen.

Removal of 13 to 15 amino acids from the N terminus of bovine placental lactogen (bPL), which according to the three-dimensional structure of pGH corresponds to a nonhelical part of bPL, did not effect its secondary structure or change the monomer content of the protein preparation. However, it remarkably decreased the binding of the prolactin (PRL) type of receptors on Nb2 cells with subsequent reduction in bioactivity. The binding to the growth hormone (somatogen) receptors either did not change or was increased, resulting in an increase of somatogen receptor-mediated bioactivity. Further truncation (17-18 amino acids) resulted in a decrease of alpha-helical content and loss of binding properties and biological activity mediated through interaction of the analogues with both somatogen (3T3-F442A cells) and lactogen (PRL) receptors (NB2-11C cells). Truncation of 19-27 amino acids caused additional loss in activity, without further change in the secondary structure. Replacement of Leu28 by a more hydrophobic Phe has only minor, if any, effect on the bioactivity of bPL. Occasional point mutations due to polymerase chain reaction errors in several analogues did not seem to have any major effect on the hormone properties. It can thus be suggested that the N-terminal part of the nonhelical portion of bPL, which corresponds to the portion of the molecule that does not exist in growth hormones, is required for efficient binding to the lactogen (PRL) but not to the somatogen or unique bPL receptors. Removal of the N-terminal part of pBL changed the specificity of bPL by decreasing its PRL receptor-mediated activities and increasing its somatogen receptor-mediated activities.     

Amino acid sequence of piratoxin-II, a myotoxic lys49 phospholipase A(2) homologue from Bothrops pirajai venom

The complete amino acid sequence of the 121 amino acid residues of piratoxin II, a phospholipase A(2) like myotoxin from Bothrops pirajai venom, is reported. PrTX-II is a basic protein with a molecular mass of 13740 Da, a calculated pI of 9.03, but an experimental pI of 8.4 +/- 0.2, showing sequence similarity with other bothropic (90-99%) or non-bothropic ( approximately 80%) Lys49 PLA(2)-like myotoxins. This similarity falls to approximately 70% when this sequence is aligned with that of Asp49 PLA(2). Due to the substitution of Asp49 by Lys49 and alterations in the calcium binding loop structure, as the replacement of Gly32 by Leu32, piratoxin-II shows no PLA(2) activity when assayed on egg yolk. Piratoxin-II showed the same primary structure as piratoxin-I, except that it has Lys116 for Leu116. Despite this slightly higher basicity at the C-terminal region, piratoxin-II was shown to be less myotoxic than piratoxin-I. The change Leu --> Lys induced an alteration of the molecule surface shape and probably of the environment charge high enough to slightly decrease the myotoxic activity. When aligned with B. jararacussu bothropstoxin-I and with B. asper Basp-II, piratoxin-II revealed a single (position 132) and a quintuple (positions 17, 90, 111, 120 and 132) amino acid substitution, respectively, suggesting a common evolutionary origin for these three myotoxins.     

截短型细胞毒素Gelonin的分子构象和生物活性

为了探索免疫络合物中具杀伤靶细胞的毒素,gelonin的结构与功能的关系,根据化学合成的gelonin基因序列和3维分子构象设计了N端区Gly,Leu,Asp和/或C端区Asp,Lys,Asp,Pro,Lys缺失的gelonin. 以重组质粒pE gel为模板,在相应引物存在下,用PCR法获得5′端区和/或3′端区碱基序列缺失的gelonin基因片段. 经克隆、表达和纯化得到3种截短型gelonin（G-N3、G-C5、G-N3C5）. CD谱和荧光谱表明,完整型gelonin（G-O）与截短型gelonin的分子构象有明显的差异.它们的构象变化与类DNase活性和抑制肿瘤细胞生长的能力均为G-O≥ G-N3＞G C5＞G-N3C5. 结果再一次证明了具有α+β型结构蛋白,gelonin的构象与生物活性的一致性.     

Role of Asp187 and Gln190 in the Na+/proline symporter (PutP) of Escherichia coli

Asp187 and Gln190 were predicted as conserved and closely located at the Na(+) binding site in a topology and homology model structure of Na(+)/proline symporter (PutP) of Escherichia coli. The replacement of Asp187 with Ala or Leu did not affect proline transport activity; whereas, change to Gln abolished the active transport. The binding affinity for Na(+) or proline of these mutants was similar to that of wild-type (WT) PutP. This result indicates Asp187 to be responsible for active transport of proline without affecting the binding. Replacement of Gln190 with Ala, Asn, Asp, Leu and Glu had no effect on transport or binding, suggesting that it may not have a role in the transport. However, in the negative D187Q mutant, a second mutation, of Gln190 to Glu or Leu, restored 46 or 7% of the transport activity of WT, respectively, while mutation to Ala, Asn or Asp had no effect. Thus, side chain at position 190 has a crucial role in suppressing the functional defect of the D187Q mutant. We conclude that Asp187 is responsible for transport activity instead of coupling-ion binding by constituting the translocation pathway of the ion and Gln190 provides a suppressing mutation site to regain PutP functional activity.     

The 10th and 11th residues of short length N-terminal PTH(1-12) analogue are important for its optimum potency.

The 10th and 11th residues of parathyroid hormone PTH(1-12) analogues were substituted to study the structure and function of PTH analogues. The substitution of Ala(10) of [Ala(3,10,12)(Leu(7)/Phe(7))Arg(11)]rPTH(1-12)NH(2) with Glu(10) and/or the Arg(11) with Ile(11) markedly decreased cAMP generating activity. Data from circular dichroism (CD) and the nuclear magnetic resonance (NMR) structural analysis of [Ala(3,10,12)(Leu(7)/Phe(7))Arg(11)]rPTH(1-12)NH(2) revealed tight alpha-helical structures, while the Glu(10) and/or Ile(11) substituted analogues showed unstable alpha-helical structures. We conclude that 10th and 11th residues are important for stabilizing its helical conformation and that destabilization of the alpha-helical structure, induced by substituting the above residues, remarkably affect its biological potency.     

The amino acid sequence of the phospholipase A2 isoenzyme from porcine pancreas

The primary structure of porcine pancreatic isophospholipase A2 (EC 3.1.1.4) has been investigated. The sequence of procine isophospholipase differs from the sequence of porcine phospholipasy by four substitutions; viz. Ala12 leads to Thr; His17 leads to Asp leads to; Met20 leads to Leu and Glu71 leads to Asn.